Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80 mL: a prospective randomized study

Objectives To compare the efficacy and safety of transurethral enucleation and resection of the prostate ( TUERP ) and transvesical prostatectomy ( TVP ) for patients with benign prostatic hyperplasia ( BPH ) and prostate volumes >80 mL. Patients and Methods A total of 100 patients with urodynamic obstruction and prostate volume >80 mL were prospectively randomized and enrolled in the study at a tertiary hospital. Patients underwent TVP or TUERP performed by one of two surgeons with experience of a large number of cases. All patients were preoperatively evaluated using patient age, prostate volume measurement, clinical characteristics of digital rectal examination, self‐assessment using the I nternational P rostate S ymptom S cores ( IPSS ) questionnaire, a quality‐of‐life ( QoL ) questionnaire, maximum urinary flow rate ( Q max ), post‐void residual urine volume ( PVR ), urine analysis, blood sample analysis, including determination of prostate‐specific antigen ( PSA ) and haemoglobin concentration. All patients were assessed peri‐operatively and postoperatively at 3 and 12 months. All complications were documented. Results Of 100 patients eligible to participate, 92 patients completed 12 months of follow‐up. Patients who underwent TUERP had shorter catheterization times and hospital stays. Operation duration was not significantly different between the two surgical groups ( P = 0.107). The resected adenoma weight in the TVP group was more than that in the TUERP group, but the difference was not significant ( P = 0.062). There were no significant differences in IPSS , PVR , Q max or QoL scores between the groups at 3 and 12 months. The patients in the TVP group appeared to have a better Q max at 3 months, however, the difference was not significant ( P = 0.081). Adverse events were similar in the two groups. Conclusion We found that TUERP had efficacy and safety equivalent to that of TVP for patients with BPH and prostate volume >80 mL.